

Prospective Registry Study on the Implementation of Simultaneous Postoperative Radiochemotherapy for Salivary Gland Carcinomas of the Head and Neck Region

NCT06464198

Status	RECRUITING
Sponsor	University of Erlangen-Nürnberg Medical School
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (9)

- Salivary gland carcinomas of the major and minor salivary glands of the head and neck region
- High-grade histology
- Successful oncological resection with curative intent
- pT3-4 or pN1-3 or Pn1 (perineural sheath infiltration) or pT1-2 with scarce or positive resection margin
- cM0

... and 4 more (see full listing online)

Exclusion (7)

- Distant metastases
- Other cancer in the last 5 years prior to study inclusion (with the exception of: adequately treated skin cancer (except melanoma) or lentigo maligno or adequately treated carcinoma in situ, in each case without evidence of active disease).
- Previous chemotherapy or radiotherapy for salivary gland carcinoma
- Previous radiotherapy in the head and neck area
- Pre-existing uncontrolled disease that constitutes a contraindication to simultaneous combination chemotherapy (e.g. signs of acute heart failure, myocardial infarction within the last 6 months before the start of therapy, congestive heart failure, heart disease with New York Heart Association (NYHA) III or IV classification, active and therapy-resistant infection, pre-existing or concomitant immunodeficiency syndrome)

... and 2 more (see full listing online)

Locations (1 total)

Erlangen, Universitätsklinikum Strahlenklinik, Erlangen, Germany

<https://clinicaltrials.gov/study/NCT06464198>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).